
|Articles|December 14, 2021
Daily Medication Pearl: Gabapentin Enacarbil (Horizant)
Author(s)Saro Arakelians, PharmD
Gabapentin enacarbil treats moderate-to-severe primary restless leg syndrome and postherpetic neuralgia.
Advertisement
Medication Pearl of the Day: Gabapentin Enacarbil (Horizant)
Indication: Gabapentin enacarbil is indicated for the treatment of moderate-to-severe primary restless legs syndrome (RLS) in adults and the management of postherpetic neuralgia (PHN) in adults.
Insight:
- Dosing: For RLS, 600 mg once daily taken at about 5 pm. A dose of 1200 mg once daily provided no additional benefit compared with the 600-mg dose, but caused an increase in adverse reactions.
- Dosage forms: Extended-release tablets 300 mg and 600 mg.
- Adverse events (AEs): Most common AEs (≥10% and at least 2 times the rate of placebo) were somnolence/sedation and dizziness.
- Mechanism of action: Gabapentin prevents pain-related responses in several models of neuropathic pain in humans.
- Manufacturer: Arbor Pharmaceuticals
Sources:
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Tradipitant Becomes First Treatment Approved for Vomiting Due to Motion Sickness in 4 Decades
2
FDA Approves Denosumab Biosimilars Boncresa and Oziltus for Osteoporosis-, Cancer-Related Bone Loss
3
'Beyond Weight Loss': Emerging Studies Show How GLP-1 Receptor Agonists May Impact Addiction Behaviors
4
New Drug Approach Targets KRAS-Mutant Lung Cancer to Overcome Therapy Resistance
5












































































































































































































